Lymphoma is a malignant tumor that may not be completely cured, but can only be controlled through various treatments to destroy the tumor and prevent recurrence and metastasis. The prognosis of lymphoma varies significantly depending on the typing and staging. The prognosis of Hodgkin’s lymphoma is best for the lymphocyte-dominant type, with a five-year survival rate of 94.3%. In contrast, the lymphocyte-depleted type is the worst, with a five-year survival rate of only 27.4%. The nodular sclerosis and mixed cell type are in between. The clinical stage of Hodgkin’s lymphoma, the five-year survival rate was 92.5% for stage I; stage II, 86.3%, stage III, 69.54%, and stage IV, 31.9%. The prognosis is generally worse in children and the elderly than in young and middle-aged people. The prognosis of non-Hodgkin’s lymphoma is equally important in terms of pathological staging and staging, and patients with aggressive lymphoma are more heterogeneous, with large differences in patient prognosis. The course of non-Hodgkin’s lymphoma in the low malignancy group is relatively mild and lacks effective radical treatment, so it has a chronic course with multiple relapses and also death due to transformation to other types and resistance to chemotherapy, but the low malignancy group can have a survival of 5-10 years or even longer if detected early and treated reasonably. Some highly malignant lymphomas are sensitive to radiotherapy, and with reasonable treatment, survival can also be significantly prolonged.